ID   IMR/KAT100
AC   CVCL_A8UT
DR   cancercelllines; CVCL_A8UT
DR   IARC_TP53; 26505
DR   Wikidata; Q108820545
RX   PubMed=17974978;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:2761; Dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate (Antimony potassium tartrate; KAT).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (PubMed=17974978).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0346 ! IMR-32
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=17974978; DOI=10.1158/0008-5472.CAN-06-4345;
RA   Xue C.-Y., Haber M., Flemming C., Marshall G.M., Lock R.B.,
RA   MacKenzie K.L., Gurova K.V., Norris M.D., Gudkov A.V.;
RT   "p53 determines multidrug sensitivity of childhood neuroblastoma.";
RL   Cancer Res. 67:10351-10360(2007).
//